ArticleHormones & cancer2013
BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients.
Article in Hormones & cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Identification of Critical Genes Related to Breast Cancer with Brain Metastasis Through Bioinformatics Analysis.Current medicinal chemistry · 2026Article
- BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities.Frontiers in genetics · 2026Review
- Developing a gene expression classifier for breast cancer diagnosis.Medical & biological engineering & computing · 2025Article
- BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.BMC immunology · 2025Article
- Article
- BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma.Scientific reports · 2023Article
- A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.British journal of cancer · 2022Article
- Article
- Article
- D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation.Histology and histopathology · 2021Article
- Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.Medicina (Kaunas, Lithuania) · 2021Review
- Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common andFrontiers in cell and developmental biology · 2021Article
- Screening and Identification of Key Common and Specific Genes and Their Prognostic Roles in Different Molecular Subtypes of Breast Cancer.Frontiers in molecular biosciences · 2021Article
- Article
- BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation.Oncology letters · 2020Article
- Article
- Mutant Proteomics of Lung Adenocarcinomas Harboring DifferentFrontiers in oncology · 2020Article
- Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers.Molecular diagnosis & therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitotic checkpoint is a fundamental mechanism involved in fidelity mitotic chromosome segregation, and its alteration results in progression of human malignancies. In this study, we examined expression profiles of seven mitotic checkpoint genes in 20 breast carcinomas using microarray analysis. Results demonstrated that BUB1 expression level was closely correlated with the proliferation activity evaluated by Ki-67 labeling index (LI) of individual cases. Therefore, we further immunolocalized BUB1 in 104 breast carcinoma tissues in order to evaluate its clinicopathological significance. BUB1 immunoreactivity was detected in the nucleus and/or cytoplasm of carcinoma cells, and nuclear and cytoplasmic BUB1 status were positive in 40% and 58% of the cases examined, respectively. In particular, nuclear BUB1 status was significantly associated with stage, pathological tumor factors, lymph node metastasis, distant metastasis, histological grade, and Ki-67 LI, but cytoplasmic BUB1 status was not significantly associated with any of the parameters examined. Subsequent multivariate analysis revealed that nuclear BUB1 status turned out an independent prognostic factor for both disease-free and breast cancer-specific survival of the patients examined. These results all indicated that BUB1 played important roles in the proliferation and/or progression of the breast carcinoma, and nuclear BUB1 immunohistochemical status is also considered a potent prognostic factor in human breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.